This reduction was probably due to a decrease in RAD51 protein levels in response to treatment with the PI3K-inhibitor (data not shown) suggesting that PI3K inhibition directly impacts HR functionality in our studied cancer cells. This evidence concerns the gene RAD51 and cancer.